| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
66: Adjuvant chemotherapy dose delivery for completely resected NSCLC in a regional cancer centre: analysis of outcomes by age and comorbidity
|
Wood, S.
|
|
2015
|
87 |
S1 |
p. S26-
1 p.
|
artikel
|
| 2 |
104: An assessment of patient and doctor views of performance status in outpatient lung cancer patients
|
Teh, H.P.
|
|
2015
|
87 |
S1 |
p. S38-S39
2 p.
|
artikel
|
| 3 |
127: An audit of online cone beam CT (CBCT) verification data for stereotactic ablative radiotherapy (SABR)
|
Mendes, R.
|
|
2015
|
87 |
S1 |
p. S46-
1 p.
|
artikel
|
| 4 |
54: An evaluation of lysine demethylase family members in malignant pleural mesothelioma
|
Breslin, M.
|
|
2015
|
87 |
S1 |
p. S21-S22
2 p.
|
artikel
|
| 5 |
103: An exploratory study into the supportive care needs of lung cancer patients at diagnosis
|
Peat, N.
|
|
2015
|
87 |
S1 |
p. S38-
1 p.
|
artikel
|
| 6 |
119: An investigation of low lung cancer histological completeness rates in a large UK hospital trust
|
O'Donnell, P.
|
|
2015
|
87 |
S1 |
p. S43-S44
2 p.
|
artikel
|
| 7 |
12: A novel investigation of ERK phosphostatus in non-small cell lung cancer
|
Harrison, R.C.
|
|
2015
|
87 |
S1 |
p. S5-
1 p.
|
artikel
|
| 8 |
141: A planning comparison study implementing "AAA" heterogeneity calculation algorithm for stage II/III non-small cell lung cancer (NSCLC): is IMRT always the solution?
|
Aznar-Garcia, L.
|
|
2015
|
87 |
S1 |
p. S51-
1 p.
|
artikel
|
| 9 |
11: Application of SureSeq solid tumour panel sequencing to a panel of FFPE samples of non small cell lung cancer from the Liverpool lung project
|
Hyde, R.
|
|
2015
|
87 |
S1 |
p. S5-
1 p.
|
artikel
|
| 10 |
32: A proposal for minimum quality standards for EBUS-TBNA outcomes
|
Evison, M.
|
|
2015
|
87 |
S1 |
p. S13-
1 p.
|
artikel
|
| 11 |
106: A qualitative study to explore carer perception and experience of end of life care following an individual's death from mesothelioma
|
Darlison, L.
|
|
2015
|
87 |
S1 |
p. S39-
1 p.
|
artikel
|
| 12 |
150: A re-audit of mortality rates after palliative radiotherapy for lung cancer from a single UK radiotherapy centre
|
Chan, C.
|
|
2015
|
87 |
S1 |
p. S54-
1 p.
|
artikel
|
| 13 |
77: Are EGFR (epidermal growth factor receptor) mutant lung cancers neurotropic and pleurotropic?
|
Bulusu, V.R.
|
|
2015
|
87 |
S1 |
p. S30-
1 p.
|
artikel
|
| 14 |
67: A retrospective audit of adjuvant chemotherapy in stage Ib–IIIb non small cell lung cancer – the Northern Ireland experience 2004–2012
|
Campbell, L.
|
|
2015
|
87 |
S1 |
p. S26-S27
2 p.
|
artikel
|
| 15 |
165: A retrospective survey of outcomes for patients diagnosed with small cell lung cancer in Leicester
|
Chauhan, M.
|
|
2015
|
87 |
S1 |
p. S60-
1 p.
|
artikel
|
| 16 |
83: A review of the first 10 months of screening selected patients for the ALK translocation using immunohistochemistry, and their subsequent treatment
|
Viola, P.
|
|
2015
|
87 |
S1 |
p. S32-S33
2 p.
|
artikel
|
| 17 |
42: Are we correctly diagnosing clinical lung cancer?
|
Smith, S.
|
|
2015
|
87 |
S1 |
p. S17-
1 p.
|
artikel
|
| 18 |
57: Are we over-extended in the surgical treatment of mesothelioma? – The tale of the unnecessary phrenectomy
|
Sharkey, A.
|
|
2015
|
87 |
S1 |
p. S23-
1 p.
|
artikel
|
| 19 |
111: Are your lung cancer patients missing out on compensation? The importance of documenting asbestos exposure and occupational history
|
Tisi, S.
|
|
2015
|
87 |
S1 |
p. S40-S41
2 p.
|
artikel
|
| 20 |
144: A single centre's experience of toxicity, compliance and survival in patients with stage III locally advanced non-small cell lung cancer (LA-NSCLC) treated with concurrent chemo-radiotherapy (CCTRT)
|
Hague, C.
|
|
2015
|
87 |
S1 |
p. S52-S53
2 p.
|
artikel
|
| 21 |
139: Assessment of radiation induced gross target volume (GTV) changes using weekly cone-beam CT (CBCT) for NSCLC
|
Duffton, A.
|
|
2015
|
87 |
S1 |
p. S50-
1 p.
|
artikel
|
| 22 |
33: A tissue diagnosis in PS 3 patients with suspected lung cancer? Safety and diagnostic outcomes with EBUS-TBNA
|
Al-Najjar, H.
|
|
2015
|
87 |
S1 |
p. S13-S14
2 p.
|
artikel
|
| 23 |
147: Audit of chemoradiotherapy (CRT) in locally advanced non-small cell lung cancer
|
Wong, S.-L.
|
|
2015
|
87 |
S1 |
p. S53-
1 p.
|
artikel
|
| 24 |
41: Audit of 'non-small cell lung cancer not – otherwise specified' diagnoses within the Northern Lung Cancer Network
|
McBrearty, C.T.
|
|
2015
|
87 |
S1 |
p. S16-
1 p.
|
artikel
|
| 25 |
72: Audit of outcomes of NSCLC patients treated with first line EGFR inhibitors in North East England
|
Margetts, J.
|
|
2015
|
87 |
S1 |
p. S28-
1 p.
|
artikel
|
| 26 |
71: Audit of the epidermal growth factor tyrosine kinase (EGFR) and anaplastic lymphoma kinase (ALK) mutation request pathway in non-squamous non-small cell lung cancer (NSCLC) in Kent
|
Taylor, H.
|
|
2015
|
87 |
S1 |
p. S28-
1 p.
|
artikel
|
| 27 |
151: A UK survey of the practice of re-irradiation of locally relapsed lung cancers after previous thoracic radiotherapy
|
Ghosal, N.
|
|
2015
|
87 |
S1 |
p. S54-S55
2 p.
|
artikel
|
| 28 |
Author index
|
|
|
2015
|
87 |
S1 |
p. S73-S78
6 p.
|
artikel
|
| 29 |
28: Brain metastases are uncommon in early tumours (T1a, T1b, N0) treated radically by VATS lobectomy, making routine brain imaging unnecessary in this group
|
McManus, K.
|
|
2015
|
87 |
S1 |
p. S11-
1 p.
|
artikel
|
| 30 |
108: Can a patient/carer information and support group address the unmet needs of people affected by mesothelioma?
|
Bolton, S.
|
|
2015
|
87 |
S1 |
p. S40-
1 p.
|
artikel
|
| 31 |
82: Can CEA or other tumour markers be useful to monitor ALK-translocation bearing adenocarcinoma of the lung?
|
Crawford, M.
|
|
2015
|
87 |
S1 |
p. S32-
1 p.
|
artikel
|
| 32 |
30: Can chest physicians perform CT biopsy? What factors influence diagnostic success and complications?
|
James, F.
|
|
2015
|
87 |
S1 |
p. S12-
1 p.
|
artikel
|
| 33 |
13: Case and literature review of pemetrexed induced pneumonitis
|
Bhattacharya, I.S.
|
|
2015
|
87 |
S1 |
p. S5-S6
2 p.
|
artikel
|
| 34 |
16: Case report: a rare tumour in thoracic oncology, frequently misdiagnosed at presentation
|
Evison, M.
|
|
2015
|
87 |
S1 |
p. S6-S7
2 p.
|
artikel
|
| 35 |
6: CeO2 nanoparticles conjugated with small molecule MET kinase inhibitor reduces the biological activity of human malignant pleural mesothelioma cell lines
|
Mohamed, B.M.
|
|
2015
|
87 |
S1 |
p. S3-
1 p.
|
artikel
|
| 36 |
98: Changes in the lung cancer nurse specialist referral criteria for inpatients with a suspected lung cancer diagnosis
|
Hughes, J.
|
|
2015
|
87 |
S1 |
p. S37-
1 p.
|
artikel
|
| 37 |
1: Circulating tumour cells from small cell lung cancer patients are tumourigenic
|
Hodgkinson, C.
|
|
2015
|
87 |
S1 |
p. S1-
1 p.
|
artikel
|
| 38 |
65: Cisplatin vs carboplatin in adjuvant NSCLC chemotherapy
|
Haridass, A.
|
|
2015
|
87 |
S1 |
p. S25-S26
2 p.
|
artikel
|
| 39 |
161: Clinical experience with oral topotecan in relapsed small cell lung cancer patients following irinotecan–platinum chemotherapy
|
Behera, D.
|
|
2015
|
87 |
S1 |
p. S58-
1 p.
|
artikel
|
| 40 |
63: Comparative toxicity profiles of two platinum doublets: real life experience from a cancer unit
|
Jessop, S.
|
|
2015
|
87 |
S1 |
p. S25-
1 p.
|
artikel
|
| 41 |
78: Complete pathological response after TK-inhibitor therapy in adenocarcinoma of the lung. The role of surgery
|
Solli, P.
|
|
2015
|
87 |
S1 |
p. S30-S31
2 p.
|
artikel
|
| 42 |
55: Contrast-enhanced magnetic resonance imaging as a marker of tumour angiogenesis in malignant pleural mesothelioma
|
Tsim, S.
|
|
2015
|
87 |
S1 |
p. S22-
1 p.
|
artikel
|
| 43 |
149: Correlation between graded prognostic assessment (GPA) and survival in primary lung cancer patients with brain metastases treated with stereotactic radiosurgery
|
Lee, H.
|
|
2015
|
87 |
S1 |
p. S54-
1 p.
|
artikel
|
| 44 |
29: CT guided wire localisation of suspicious pulmonary lesions; a review of 10 patients
|
Daly, A.
|
|
2015
|
87 |
S1 |
p. S11-S12
2 p.
|
artikel
|
| 45 |
138: Cyberknife® for early stage non-small cell lung cancer (NSCLC) at a tertiary referral centre – results of the first year of treatment at Birmingham
|
Stevenson, R.
|
|
2015
|
87 |
S1 |
p. S50-
1 p.
|
artikel
|
| 46 |
4: DHMEQ a novel therapeutic option for the treatment of inflammatory mediated cisplatin resistant non-small cell lung cancer
|
Baird, A.-M.
|
|
2015
|
87 |
S1 |
p. S2-
1 p.
|
artikel
|
| 47 |
38: Diagnostic rate of physician performed cutting needle pleural biopsy
|
Anwar, N.
|
|
2015
|
87 |
S1 |
p. S15-
1 p.
|
artikel
|
| 48 |
27: Diagnostic utility of unbiased circulating-tumour cell capture through negative depletion of peripheral blood cells
|
Freydin, D.V.
|
|
2015
|
87 |
S1 |
p. S10-S11
2 p.
|
artikel
|
| 49 |
60: Discontinuation of maintenance pemetrexed (mPEM) in non-small cell lung cancer (NSCLC) due to renal failure
|
Charlton, P.
|
|
2015
|
87 |
S1 |
p. S24-
1 p.
|
artikel
|
| 50 |
40: Do histology 'not otherwise specified' rates influence survival?
|
Caprario, C.
|
|
2015
|
87 |
S1 |
p. S16-
1 p.
|
artikel
|
| 51 |
113: Do standardised uptake values from PET-CT scans predict EGFR status of lung tumours?
|
Coote, J.H.
|
|
2015
|
87 |
S1 |
p. S41-
1 p.
|
artikel
|
| 52 |
114: Early endobronchial intervention to maintain performance status for oncological therapy: a case series
|
Griffin, L.
|
|
2015
|
87 |
S1 |
p. S41-S42
2 p.
|
artikel
|
| 53 |
Editorial board
|
|
|
2015
|
87 |
S1 |
p. i-
1 p.
|
artikel
|
| 54 |
81: Efficacy and safety of AP26113 in ALK+ non-small cell lung cancer (NSCLC), including patients with brain metastases
|
Gettinger, S.N.
|
|
2015
|
87 |
S1 |
p. S32-
1 p.
|
artikel
|
| 55 |
9: EGFR mutations: are exon 19 deletions and L858R different in the real world setting?
|
Davies, R.S.
|
|
2015
|
87 |
S1 |
p. S4-
1 p.
|
artikel
|
| 56 |
124: Electronic cigarette use and risk perception in a Stop Smoking Service in England
|
Sherratt, F.
|
|
2015
|
87 |
S1 |
p. S45-
1 p.
|
artikel
|
| 57 |
168: Endobronchial cryotherapy in the management and palliation of malignant airway disease
|
Ryan, S.A.
|
|
2015
|
87 |
S1 |
p. S61-S62
2 p.
|
artikel
|
| 58 |
61: Evolving paradigms in the treatment of advanced lung adenocarcinoma: an audit of first line treatment outcomes over a 7 year period
|
Needham, S.E.
|
|
2015
|
87 |
S1 |
p. S24-S25
2 p.
|
artikel
|
| 59 |
128: Experience of lung stereotactic ablative body radiotherapy (SABR) in a non-academic cancer centre in the UK
|
Shahid Iqbal, M.
|
|
2015
|
87 |
S1 |
p. S46-S47
2 p.
|
artikel
|
| 60 |
115: Exploring the incidence of venous thromboembolism amongst thoracic oncology outpatients; time for thromboprophylaxis?
|
Samani, A.
|
|
2015
|
87 |
S1 |
p. S42-
1 p.
|
artikel
|
| 61 |
120: Factors affecting the risk of brain metastases following radical treatment of lung cancer
|
Al-Ameri, A.
|
|
2015
|
87 |
S1 |
p. S44-
1 p.
|
artikel
|
| 62 |
179: Falling surgical resection rates; how accurate is LUCADA?
|
Shiferaw, D.
|
|
2015
|
87 |
S1 |
p. S66-
1 p.
|
artikel
|
| 63 |
171: First UK experience of robotically assisted pulmonary lobectomy using the DaVinci SI
|
Slight, R.
|
|
2015
|
87 |
S1 |
p. S63-
1 p.
|
artikel
|
| 64 |
186: Forecasting patient recruitment for time-to-event analysis in National Lung Matrix Trial
|
Brock, K.
|
|
2015
|
87 |
S1 |
p. S69-
1 p.
|
artikel
|
| 65 |
175: From zero to sixty-seven percent, from one consultant to all. What to expect next? Review of VATS lobectomy programme in Norfolk and Norwich University Hospital
|
Kadlec, J.
|
|
2015
|
87 |
S1 |
p. S64-
1 p.
|
artikel
|
| 66 |
105: Guideline for patient information on enhanced recovery in thoracic surgery
|
Mitchell, J.
|
|
2015
|
87 |
S1 |
p. S39-
1 p.
|
artikel
|
| 67 |
152: 25 Gy in 5 fractions in one week as palliative radiotherapy in NSCLC
|
Jones, S.
|
|
2015
|
87 |
S1 |
p. S55-
1 p.
|
artikel
|
| 68 |
44: Haemoptysis with a normal chest X-ray – what are the yields of CT and bronchoscopy?
|
Raju, R.S.
|
|
2015
|
87 |
S1 |
p. S17-S18
2 p.
|
artikel
|
| 69 |
118: Has our lower local histological confirmation rate affected patient care?
|
Abdulla, M.A.
|
|
2015
|
87 |
S1 |
p. S43-
1 p.
|
artikel
|
| 70 |
31: High uptake values on PET results in a number of unnecessary lung resections, despite MDT discussion and attempts to obtain tissue preoperatively
|
McManus, K.
|
|
2015
|
87 |
S1 |
p. S12-S13
2 p.
|
artikel
|
| 71 |
21: How long does it take from referral to a diagnosis of lung cancer?
|
Caprario, C.
|
|
2015
|
87 |
S1 |
p. S8-S9
2 p.
|
artikel
|
| 72 |
164: Hyponatraemia in small cell lung cancer
|
Wood, G.E.
|
|
2015
|
87 |
S1 |
p. S59-S60
2 p.
|
artikel
|
| 73 |
53: Immunotherapy of malignant pleural mesothelioma using MET specific T-cells
|
Thayaparan, T.
|
|
2015
|
87 |
S1 |
p. S21-
1 p.
|
artikel
|
| 74 |
132: Implementation of stereotactic ablative body radiotherapy (SABR) for early stage medically inoperable lung cancer: an experience from a medium size clinical centre
|
Tambe, N.S.
|
|
2015
|
87 |
S1 |
p. S48-
1 p.
|
artikel
|
| 75 |
123: Improving lung cancer survival in Merseyside 2007–2012
|
Kelly, V.
|
|
2015
|
87 |
S1 |
p. S45-
1 p.
|
artikel
|
| 76 |
90: Improving survivorship through pre-habilitation at the start of the journey for lung cancer and mesothelioma
|
Clayton, K.J.
|
|
2015
|
87 |
S1 |
p. S35-
1 p.
|
artikel
|
| 77 |
142: IMRT for treating lung cancer – our experience at Northampton General Hospital
|
Vaidya, D.
|
|
2015
|
87 |
S1 |
p. S51-S52
2 p.
|
artikel
|
| 78 |
101: Increasing input from research nurse and lung CNS improves recruitment to clinical trials
|
Clayton, K.J.
|
|
2015
|
87 |
S1 |
p. S37-S38
2 p.
|
artikel
|
| 79 |
135: Intra-fractional tumour motion and an isotropic margin: lung stereotactic ablative body radiotherapy treatment – practice evaluation
|
Chauhan, S.
|
|
2015
|
87 |
S1 |
p. S49-
1 p.
|
artikel
|
| 80 |
140: Isotoxic intensity modulated radiotherapy (IMRT) in stage III non small cell lung cancer (NSCLC) – a feasibility study
|
Faivre-Finn, C.
|
|
2015
|
87 |
S1 |
p. S51-
1 p.
|
artikel
|
| 81 |
125: LUCADA and median survival in lung cancer
|
Caprario, C.
|
|
2015
|
87 |
S1 |
p. S45-S46
2 p.
|
artikel
|
| 82 |
23: LUCADA – are we doing better than the data suggests?
|
Fuller, J.
|
|
2015
|
87 |
S1 |
p. S9-
1 p.
|
artikel
|
| 83 |
189: Lung ART: phase III study comparing post-operative conformal radiotherapy to no post-operative radiotherapy in patients with completely resected non-small cell lung cancer and mediastinal N2 involvement
|
Faivre-Finn, C.
|
|
2015
|
87 |
S1 |
p. S70-S71
2 p.
|
artikel
|
| 84 |
24: Lung cancer as an 'acute presentation' in acute unselected medical admissions at a district general hospital (audit at Kings Mill hospital, November 2013–May 2014)
|
Saini, G.
|
|
2015
|
87 |
S1 |
p. S9-S10
2 p.
|
artikel
|
| 85 |
22: Lung cancer diagnosed after an emergency hospital admission
|
Conroy, K.
|
|
2015
|
87 |
S1 |
p. S9-
1 p.
|
artikel
|
| 86 |
26: Lung cancer fast track referrals: evaluation of a new referral form in West Dorset
|
Stirling, S.
|
|
2015
|
87 |
S1 |
p. S10-
1 p.
|
artikel
|
| 87 |
25: Lung cancer survivorship clinic
|
White, J.
|
|
2015
|
87 |
S1 |
p. S10-
1 p.
|
artikel
|
| 88 |
122: Lung cancer treated using radiofrequency ablation: two year outcome data
|
Beeson, J.
|
|
2015
|
87 |
S1 |
p. S45-
1 p.
|
artikel
|
| 89 |
107: Lung cancer – You can avoid it, get it, survive it; an evaluation of the Irish Cancer Society's annual lung cancer awareness campaign from 2011 to 2013
|
McNamara, A.
|
|
2015
|
87 |
S1 |
p. S39-S40
2 p.
|
artikel
|
| 90 |
180: Lung resection – what is high risk?
|
Elbaroni, W.
|
|
2015
|
87 |
S1 |
p. S66-
1 p.
|
artikel
|
| 91 |
190: LungTech stereotactic body radiotherapy (SBRT) of inoperable centrally located NSCLC: a phase II study in preparation for a randomised phase III trial
|
Falk, S.
|
|
2015
|
87 |
S1 |
p. S71-
1 p.
|
artikel
|
| 92 |
177: Lymph node staging for lung cancer in a new VATS lobectomy programme; compliance to ESTS guidelines and stage migration from PET scan
|
Abah, U.
|
|
2015
|
87 |
S1 |
p. S65-
1 p.
|
artikel
|
| 93 |
143: Magnetic resonance imaging (MRI) in patients with non-small cell lung cancer (NSCLC) using active breathing coordinator motion control
|
Kaza, E.
|
|
2015
|
87 |
S1 |
p. S52-
1 p.
|
artikel
|
| 94 |
59: Maintenance pemetrexed immediately following induction treatment with pemetrexed plus cisplatin for advanced non-small-cell non-squamous carcinoma of the lung – a single institution experience
|
Kim, D.
|
|
2015
|
87 |
S1 |
p. S24-
1 p.
|
artikel
|
| 95 |
5: Mechanisms of resistance to dual PI3K–mTOR inhibition in NSCLC cell lines
|
Heavey, S.
|
|
2015
|
87 |
S1 |
p. S2-
1 p.
|
artikel
|
| 96 |
45: Medical thoracoscopy: outcomes and complications of procedures carried out over a 12 month period
|
Tedd, H.
|
|
2015
|
87 |
S1 |
p. S18-
1 p.
|
artikel
|
| 97 |
137: Mentorship, development and implementation of SABR for NSCLC: the Bristol experience
|
Mason, J.
|
|
2015
|
87 |
S1 |
p. S50-
1 p.
|
artikel
|
| 98 |
51: MesobanK: quality control of tumour samples
|
Knight, J.
|
|
2015
|
87 |
S1 |
p. S20-S21
2 p.
|
artikel
|
| 99 |
3: MicroRNA-31 expression mediates chemoresistance in malignant pleural mesothelioma
|
Moody, H.L.
|
|
2015
|
87 |
S1 |
p. S1-S2
2 p.
|
artikel
|
| 100 |
109: Midterm pulmonary function follow up in patients with lung cancer radiofrequency ablation
|
Skondras, E.
|
|
2015
|
87 |
S1 |
p. S40-
1 p.
|
artikel
|
| 101 |
70: Molecular analysis in advanced NSCLC are we doing the best we can?
|
Davies, R.S.
|
|
2015
|
87 |
S1 |
p. S27-
1 p.
|
artikel
|
| 102 |
39: Mutation analysis and association with TTF1 expression in lung non-squamous NSCLC
|
Kret, A.
|
|
2015
|
87 |
S1 |
p. S16-
1 p.
|
artikel
|
| 103 |
187: National Lung Matrix Trial: multi-drug, genetic marker-directed, non-comparative, multi-centre, multi-arm phase II trial in non-small cell lung cancer
|
Middleton, G.
|
|
2015
|
87 |
S1 |
p. S69-S70
2 p.
|
artikel
|
| 104 |
159: Neutropenic sepsis in patients receiving chemotherapy for small cell lung cancer
|
Chauhan, M.
|
|
2015
|
87 |
S1 |
p. S57-S58
2 p.
|
artikel
|
| 105 |
97: New approaches to lung cancer care
|
Ball, H.
|
|
2015
|
87 |
S1 |
p. S36-S37
2 p.
|
artikel
|
| 106 |
47: New pleural service – a first review
|
Phitidis, M.E.
|
|
2015
|
87 |
S1 |
p. S19-
1 p.
|
artikel
|
| 107 |
Notes to authors
|
|
|
2015
|
87 |
S1 |
p. S79-
1 p.
|
artikel
|
| 108 |
170: Novel thoraco-abdominal analysis technology can measure early respiratory changes following lung cancer resection
|
Elshafie, G.
|
|
2015
|
87 |
S1 |
p. S62-S63
2 p.
|
artikel
|
| 109 |
73: Oligo-recurrence on tyrosine kinase inhibitors: is radiotherapy an option?
|
Davies, R.S.
|
|
2015
|
87 |
S1 |
p. S28-S29
2 p.
|
artikel
|
| 110 |
46: Operator sensitivity for pleural malignancy at medical thoracoscopy
|
Gunatilake, S.
|
|
2015
|
87 |
S1 |
p. S18-S19
2 p.
|
artikel
|
| 111 |
131: Optimisation of stereotactic ablative body radiotherapy (SABR) planning: the Hull method
|
Tambe, N.S.
|
|
2015
|
87 |
S1 |
p. S47-S48
2 p.
|
artikel
|
| 112 |
126: Our experience in treating lung tumours using stereotactic ablative body radiotherapy (SABR) at Northampton General Hospital
|
Yusof, H.
|
|
2015
|
87 |
S1 |
p. S46-
1 p.
|
artikel
|
| 113 |
156: Outcome for performance status 2–3 patients undergoing hypo-fractionated radical radiotherapy for NSCLC
|
Hsu, J.K.
|
|
2015
|
87 |
S1 |
p. S56-S57
2 p.
|
artikel
|
| 114 |
153: Outcome of stage III inoperable non-small cell lung cancer (NSCLC) treated with radical intent
|
Shahid Iqbal, M.
|
|
2015
|
87 |
S1 |
p. S55-
1 p.
|
artikel
|
| 115 |
176: Outcome of surgery versus radiotherapy after induction treatment in patients with N2 disease: systematic review and meta-analysis of randomised trials
|
McElnay, P.J.
|
|
2015
|
87 |
S1 |
p. S65-
1 p.
|
artikel
|
| 116 |
50: Outcomes of patients with malignant pleural mesothelioma treated with first line palliative cisplatin and pemetrexed chemotherapy, in South Yorkshire
|
Taylor, F.
|
|
2015
|
87 |
S1 |
p. S20-
1 p.
|
artikel
|
| 117 |
91: Paronychia side effects of targeted therapies and their management
|
Dickson, J.
|
|
2015
|
87 |
S1 |
p. S35-
1 p.
|
artikel
|
| 118 |
76: Patterns of extra-cranial disease progression in epidermal growth factor receptor (EGFR) mutant metastatic non-small cell lung cancer (NSCLC) patients on a tyrosine kinase inhibitor (TKI)
|
Aitken, K.
|
|
2015
|
87 |
S1 |
p. S30-
1 p.
|
artikel
|
| 119 |
69: Pemetrexed in the treatment of non-small-cell lung cancer
|
Cash, R.
|
|
2015
|
87 |
S1 |
p. S27-
1 p.
|
artikel
|
| 120 |
112: Performance status (PS): is there a correlation between doctor and patient?
|
Clayton, K.J.
|
|
2015
|
87 |
S1 |
p. S41-
1 p.
|
artikel
|
| 121 |
183: PIT: a phase III trial of prophylactic irradiation of tracts in patients with malignant pleural mesothelioma following invasive chest wall intervention
|
Bayman, N.
|
|
2015
|
87 |
S1 |
p. S68-
1 p.
|
artikel
|
| 122 |
121: Place and cause of death in patients with lung cancer in the United Kingdom
|
O'Dowd, E.L.
|
|
2015
|
87 |
S1 |
p. S44-
1 p.
|
artikel
|
| 123 |
2: Platinum-induced DNA damage and repair mechanisms in non-small cell lung cancer
|
He, Y.
|
|
2015
|
87 |
S1 |
p. S1-
1 p.
|
artikel
|
| 124 |
56: Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy and systemic chemotherapy in malignant pleural mesothelioma. Experience in 100 consecutive patients
|
Lang-Lazdunski, L.
|
|
2015
|
87 |
S1 |
p. S22-S23
2 p.
|
artikel
|
| 125 |
154: Positron emission tomography derived parameters as predictive factors for doubling time of tumour & survival in non-small cell lung cancer patients treated with radical radiotherapy
|
Khan, M.H.
|
|
2015
|
87 |
S1 |
p. S55-S56
2 p.
|
artikel
|
| 126 |
157: Post-operative intensity modulated radiotherapy in thymoma
|
Jackson, A.H.
|
|
2015
|
87 |
S1 |
p. S57-
1 p.
|
artikel
|
| 127 |
80: Potential impact of moving to up-front ALK testing in patients with non small cell lung cancer (NSCLC); the Newcastle upon Tyne NHS Foundation Trust (NUTH) experience
|
Lambourne, B.
|
|
2015
|
87 |
S1 |
p. S31-
1 p.
|
artikel
|
| 128 |
116: Predictors of distress in lung cancer patients: a systematic review
|
McHugh, R.S.
|
|
2015
|
87 |
S1 |
p. S42-
1 p.
|
artikel
|
| 129 |
155: Predictors of failure for PS2–3 patients undergoing hypo-fractionated radical radiotherapy for NSCLC – experience of a UK centre
|
Horsley, A.
|
|
2015
|
87 |
S1 |
p. S56-
1 p.
|
artikel
|
| 130 |
102: Prospective assessment of incident respiratory symptoms in COPD (PAIRS-COPD): a feasibility study
|
Brummell, S.
|
|
2015
|
87 |
S1 |
p. S38-
1 p.
|
artikel
|
| 131 |
99: Prospective audit of a lung cancer nurse specialist telephone link line call to surgical patients 30 days post hospital discharge
|
King, M.
|
|
2015
|
87 |
S1 |
p. S37-
1 p.
|
artikel
|
| 132 |
94: Prospective audit of smoking cessation and lung cancer nurse specialist intervention within the Papworth Thoracic Oncology Service
|
King, M.
|
|
2015
|
87 |
S1 |
p. S36-
1 p.
|
artikel
|
| 133 |
184: Quality assurance programme for the isotoxic intensity modulated radiotherapy feasibility study
|
Groom, N.
|
|
2015
|
87 |
S1 |
p. S68-S69
2 p.
|
artikel
|
| 134 |
188: Quality of life after treatment for brain metastases: final demographic data from the QUARTZ trial
|
Mulvenna, P.
|
|
2015
|
87 |
S1 |
p. S70-
1 p.
|
artikel
|
| 135 |
84: Quality of life measures relating to the skin toxicities of tyrosine kinase inhibitor (TKI) use in lung cancer – what is in current use in the literature?
|
Watts, G.J.
|
|
2015
|
87 |
S1 |
p. S33-
1 p.
|
artikel
|
| 136 |
158: Radical radiotherapy for non-small cell lung cancer (NSCLC) using two different modalities: single centre audit outcome
|
Tripathi, D.
|
|
2015
|
87 |
S1 |
p. S57-
1 p.
|
artikel
|
| 137 |
14: Radiological demonstration of successful correction of post-pneumonectomy syndrome facilitated by intrathoracic breast implants
|
Idris, L.O.
|
|
2015
|
87 |
S1 |
p. S6-
1 p.
|
artikel
|
| 138 |
34: Rapid on site evaluation (ROSE) accurately identifies carcinoma in patients undergoing diagnostic endobronchial (EBUS)/oesophageal (EUS) ultrasound for suspected lung cancer
|
Tang, W.
|
|
2015
|
87 |
S1 |
p. S14-
1 p.
|
artikel
|
| 139 |
35: Rapid on site evaluation (ROSE) may reduce total number of passes needed to achieve definitive diagnosis in endobronchial (EBUS)/oesophageal (EUS) ultrasound for suspected lung cancer
|
Tang, W.
|
|
2015
|
87 |
S1 |
p. S14-
1 p.
|
artikel
|
| 140 |
36: Rapid on site evaluation with oesophageal ultrasound-guided FNA in the diagnosis and staging of metastatic lung cancer
|
Obaidee, S.
|
|
2015
|
87 |
S1 |
p. S14-S15
2 p.
|
artikel
|
| 141 |
89: Recognising the valuable role a lung cancer CNS can play at the start of the patient's pathway
|
Maddock, N.
|
|
2015
|
87 |
S1 |
p. S34-
1 p.
|
artikel
|
| 142 |
181: Resection rates in non-small cell lung cancer: how are we doing?
|
Bunclark, K.
|
|
2015
|
87 |
S1 |
p. S67-
1 p.
|
artikel
|
| 143 |
182: RESPECT-Meso: a multicentre non-blinded randomised controlled trial to assess the impact of regular early specialist symptom control treatment on quality of life in malignant mesothelioma
|
Gunatilake, S.
|
|
2015
|
87 |
S1 |
p. S67-S68
2 p.
|
artikel
|
| 144 |
166: REST – a Dutch/UK randomized phase III trial on the use of thoracic radiotherapy in extensive stage small-cell lung cancer
|
Faivre-Finn, C.
|
|
2015
|
87 |
S1 |
p. S60-S61
2 p.
|
artikel
|
| 145 |
133: Retrospective audit of treatment outcomes and follow up patterns in patients with non-small cell lung cancer (NSCLC) treated with SABR in South Wales
|
Holloway, J.
|
|
2015
|
87 |
S1 |
p. S48-
1 p.
|
artikel
|
| 146 |
145: Retrospective review of survival outcomes for non-small cell lung cancer (NSCLC) patients treated with radical radiotherapy since 2000 in St. Bartholomew's Hospital, London
|
Conibear, J.
|
|
2015
|
87 |
S1 |
p. S53-
1 p.
|
artikel
|
| 147 |
136: Review of CT imaging following stereotactic ablative radiotherapy for stage 1 non small cell lung cancer
|
Pascoe, A.C.
|
|
2015
|
87 |
S1 |
p. S49-S50
2 p.
|
artikel
|
| 148 |
52: Review of malignant pleural mesothelioma patients receiving chemotherapy in Northern Ireland 2008–2012
|
Forde, C.
|
|
2015
|
87 |
S1 |
p. S21-
1 p.
|
artikel
|
| 149 |
162: Review of SCLC timelines to assessment and treatment in Northern Ireland
|
McAleese, J.
|
|
2015
|
87 |
S1 |
p. S58-S59
2 p.
|
artikel
|
| 150 |
160: Review of the national lung cancer audit of SCLC chemotherapy rates in Northern Ireland
|
Johnston, R.
|
|
2015
|
87 |
S1 |
p. S58-
1 p.
|
artikel
|
| 151 |
134: Simultaneous cone beam computed tomography (SCBCT) acquisition during volumetric modulated arc therapy (VMAT) for stereotactic ablative radiotherapy (SART): a clinical quality assurance method with simultaneous and periradiotherapy CBCT-IGRT
|
Aznar-Garcia, L.
|
|
2015
|
87 |
S1 |
p. S48-S49
2 p.
|
artikel
|
| 152 |
169: Stenting of central airway tumours with the flexible bronchoscope
|
Venn, R.M.
|
|
2015
|
87 |
S1 |
p. S62-
1 p.
|
artikel
|
| 153 |
129: Stereotactic ablative body radiotherapy (SABR) for early stage non-small cell lung cancer (NSCLC) at a tertiary referral centre results of the first year of treatment at Birmingham
|
Stevenson, R.
|
|
2015
|
87 |
S1 |
p. S47-
1 p.
|
artikel
|
| 154 |
130: Stereotactic ablative radiotherapy (SABR) for early stage, medically inoperable non-small cell lung cancer (NSCLC): initial outcomes from 2 years' experience at the Oxford Cancer Centre, Oxford University Hospitals NHS Trust
|
Hill, E.
|
|
2015
|
87 |
S1 |
p. S47-
1 p.
|
artikel
|
| 155 |
49: Success rate of local anaesthetic video assisted thoracoscopy (LAVAT) talc poudrage for malignant pleural effusions at a UK tertiary centre
|
Tufail, M.
|
|
2015
|
87 |
S1 |
p. S20-
1 p.
|
artikel
|
| 156 |
17: Surgery for lung cancer in nonagenarians: a new dawn approaches
|
Ghosh-Dastidar, M.
|
|
2015
|
87 |
S1 |
p. S7-
1 p.
|
artikel
|
| 157 |
68: Surgical resection and adjuvant chemotherapy in non small cell lung cancer (NSCLC): a review of practice in South East Wales
|
Evans, R.
|
|
2015
|
87 |
S1 |
p. S27-
1 p.
|
artikel
|
| 158 |
18: Syndrome of inappropriate antidiuretic hormone (SIADH) management in small cell lung cancer (SCLC); patient's narrative and oncologist's perspective, a case report
|
Jeffs, Y.
|
|
2015
|
87 |
S1 |
p. S7-
1 p.
|
artikel
|
| 159 |
163: Syndrome of inappropriate antidiuretic hormone (SIADH) secretion in small cell lung cancer: 12 months experience from a cancer unit
|
Bulusu, V.R.
|
|
2015
|
87 |
S1 |
p. S59-
1 p.
|
artikel
|
| 160 |
178: Systematic lymph node sampling at operation results in more node positive staging in NSCLC
|
Whiteley, J.
|
|
2015
|
87 |
S1 |
p. S65-S66
2 p.
|
artikel
|
| 161 |
85: Systemic therapy in advanced NSCLC in the older patient: a network audit of non small cell lung cancer patients
|
Wilshaw, V.
|
|
2015
|
87 |
S1 |
p. S33-
1 p.
|
artikel
|
| 162 |
37: The added value of positron emission tomography to a clinical prediction model for pulmonary nodules
|
Al-Ameri, A.
|
|
2015
|
87 |
S1 |
p. S15-
1 p.
|
artikel
|
| 163 |
79: The East Midlands' experience in the use of crizotinib in ALK positive lung cancer
|
Chauhan, M.
|
|
2015
|
87 |
S1 |
p. S31-
1 p.
|
artikel
|
| 164 |
86: The impact of age, performance status and co-morbidities in determining treatment options in elderly patients with non-small cell lung cancer (NSCLC) in Newcastle upon Tyne NHS trust (NUTH)
|
Suthermaraj, G.
|
|
2015
|
87 |
S1 |
p. S33-S34
2 p.
|
artikel
|
| 165 |
19: The impact of an acute oncology service on new lung cancer diagnoses
|
Walter, H.S.
|
|
2015
|
87 |
S1 |
p. S8-
1 p.
|
artikel
|
| 166 |
43: The impact of a national public awareness campaign for cough as a lung cancer symptom
|
Ironmonger, L.
|
|
2015
|
87 |
S1 |
p. S17-
1 p.
|
artikel
|
| 167 |
20: The importance of a well organised and appropriate referral pathway for the management of gastrointestinal incidental findings on PET-CT done for lung cancer
|
Johnstone, J.R.
|
|
2015
|
87 |
S1 |
p. S8-
1 p.
|
artikel
|
| 168 |
7: The integrin αvβ6: a new target for therapy in non-small cell lung cancer
|
Rudran, B.
|
|
2015
|
87 |
S1 |
p. S3-
1 p.
|
artikel
|
| 169 |
58: The prognostic significance of nodal metastatic burden on survival following radical surgery for malignant pleural mesothelioma
|
Sharkey, A.
|
|
2015
|
87 |
S1 |
p. S23-S24
2 p.
|
artikel
|
| 170 |
146: Therapeutic advantage of concurrent chemoradiotherapy with 55 Gy/20 fractions with cisplatinum and vinorelbine assessed by comparing control rates predicted by radio-biological (Biosuite) software and clinical results
|
Maguire, J.
|
|
2015
|
87 |
S1 |
p. S53-
1 p.
|
artikel
|
| 171 |
48: The safety profile of VATS pleural biopsy
|
Vozza, A.
|
|
2015
|
87 |
S1 |
p. S19-
1 p.
|
artikel
|
| 172 |
185: The SPECIAL trial: exploring the place of early specialist palliative care in UK lung cancer management
|
Ahmedzai, S.H.
|
|
2015
|
87 |
S1 |
p. S69-
1 p.
|
artikel
|
| 173 |
75: The use of gefitinib and erlotinib in locally advanced and metastatic EGFR mutant lung cancer – assessment of progression free survival according to mutation type
|
Atkinson, C.E.L.
|
|
2015
|
87 |
S1 |
p. S29-S30
2 p.
|
artikel
|
| 174 |
167: Thoracic radiotherapy in extensive stage small cell lung cancer
|
Harris, M.A.
|
|
2015
|
87 |
S1 |
p. S61-
1 p.
|
artikel
|
| 175 |
62: Toxicity and efficacy of oral vinorelbine and carboplatin compared with gemcitabine and carboplatin in metastatic NSCLC
|
Sayers, I.G.
|
|
2015
|
87 |
S1 |
p. S25-
1 p.
|
artikel
|
| 176 |
74: TRANSCRiPT: a study to assess Tarceva® in NSCLC with epidermal growth factor receptor mutations
|
Lewanski, C.
|
|
2015
|
87 |
S1 |
p. S29-
1 p.
|
artikel
|
| 177 |
88: Transforming lung cancer care in the community – developing and testing a new model of nursing care
|
Jeffs, Y.
|
|
2015
|
87 |
S1 |
p. S34-
1 p.
|
artikel
|
| 178 |
117: Treatment and survival trends in patients with advanced stage NSCLC: a population based study
|
Jones, G.S.
|
|
2015
|
87 |
S1 |
p. S42-S43
2 p.
|
artikel
|
| 179 |
15: Treatment of bilateral synchronous lung cancer in high risk patients: the role of single-port VATS approach and perioperative rehabilitation
|
Zakeri, R.
|
|
2015
|
87 |
S1 |
p. S6-
1 p.
|
artikel
|
| 180 |
8: Tumour molecular profiling and quantitative detection of circulating biomarkers in patients with lung cancer
|
Karampini, E.
|
|
2015
|
87 |
S1 |
p. S3-S4
2 p.
|
artikel
|
| 181 |
92: Understanding and reducing admissions to A&E; the role of the lung cancer nurse specialist
|
Walton, D.
|
|
2015
|
87 |
S1 |
p. S35-
1 p.
|
artikel
|
| 182 |
173: Uniportal VATS anatomical resection for NSCLC; is it worth the pain?
|
Anderson, M.
|
|
2015
|
87 |
S1 |
p. S63-S64
2 p.
|
artikel
|
| 183 |
93: Using your voice – how to use your nursing voice at the MDT
|
Magee, L.R.A.
|
|
2015
|
87 |
S1 |
p. S36-
1 p.
|
artikel
|
| 184 |
174: Validation of a surgical predictive score for 90 day mortality in lung cancer and comparison with Thoracoscore
|
O'Dowd, E.L.
|
|
2015
|
87 |
S1 |
p. S64-
1 p.
|
artikel
|
| 185 |
172: VATS lobectomy: the new standard for surgical resection of lung cancer?
|
Asadi, N.
|
|
2015
|
87 |
S1 |
p. S63-
1 p.
|
artikel
|
| 186 |
148: Venous thromboembolism associated with enhanced survival for patients undergoing concurrent chemoradiation (55 Gy/20f/4w plus cisplatinum and vinorelbine) for inoperable NSCLC
|
Jones, S.
|
|
2015
|
87 |
S1 |
p. S54-
1 p.
|
artikel
|
| 187 |
10: Volatile biomarkers for discrimination of lung cancer risk and mutation
|
Davies, M.P.A.
|
|
2015
|
87 |
S1 |
p. S4-S5
2 p.
|
artikel
|
Tijdschrift beschrijving